ID-CTNI is led by Professor Paddy Mallon, St Vincent’s University Hospital and University College Dublin (UCD). The ID-CTNI network is hosted at the UCD Clinical Research Centre and supported by the UCD Centre for Experimental Pathogen Host Research (CEHR).
The ID-CTNI network brings together a team with expertise in leading, directing and assisting Infectious Diseases clinical trials and investigations, both investigator and industry led. The multidisciplinary network comprises academic clinicians and researchers from:
Each of the collaborators are internationally recognised as experts in specific areas of Infectious Diseases. This streamlined network will foster a supportive environment that will help researchers to exchange knowledge and share resources in order to conduct high quality, meaningful and impactful clinical trials into infectious diseases.
The objectives of the ID-CTNI are to establish a well-structured network of researchers, facilities, and infrastructure to improve the quality of clinical trial design in infectious diseases nationally. The Network will extend existing clinical trials to other hospitals across the Network in Ireland as well as completing, from start to finish, three new collaborative clinical trials over a five-year period of this award. The Network will involve patients at every part of this research journey, from designing trials through to reporting results back to the public. This will ensure that the patient’s perspective is at the forefront of all our research activities and keep patients constantly informed of developments in the field of infectious diseases. The Network will also provide opportunity for new researchers in infectious diseases to get valuable training experience.
The ID-CTNI will network with researchers across the world by integrating our research with international networks in Europe and the US that are working in the field of infectious diseases. This will help the Centre have more impact globally; enable the Centre to access funding to ensure that its activities are sustainable over the long term; and ensure that the Centre retains a leadership role into the future in infectious diseases and pandemic response. The ID-CTNI will focus on research that provides solutions for common health problems for people in Ireland.
The unprecedented focus on Infectious Diseases arising from the COVID19 pandemic is providing opportunities for the ID-CTNI to develop international clinical trials with other clinical trials networks.
Current Multi-site Clinical Trials include:
EU-COVAT-2 BOOSTAVAC (COVID-19 Booster Vaccine Trial)
An International Multicentre, Phase 2, Randomised, Adaptive Protocol to determine need for, optimal timing of and immunogenicity of administering a 4th homologous mRNA vaccination dose against SARS-CoV-2 in the general population (18+ years) already vaccinated against SARS-CoV-2
COVIRL-002 - Tocilizumab for management of severe, non-critical COVID-19 infection.
An open-label, multi-centre, randomised trial comparing different doses of single-dose tocilizumab in adults with severe, non-critical, PCR-confirmed COVID-19 infection with evidence of progressive decline in respiratory function and evolving systemic inflammation on time to intubation, non-invasive ventilation and/or all-cause mortality.
SWIFT Study - Semaglutide’s Efficacy in Achieving Weight Loss for Those With HIV.
A randomised, controlled, parallel group, open-label definitive intervention trial evaluating the impact of a 28-week course of weekly, subcutaneous Semaglutide alongside dietary and exercise advice on weight loss, inflammation and immune function in obese people living with HIV on stable antiretroviral therapy compared to dietary and exercise advice alone.
For queries please contact:
Dr. Adriana de Araujo, Project Manager.